Research programme: potassium channel modulators - Pharmexa/Poseidon

Drug Profile

Research programme: potassium channel modulators - Pharmexa/Poseidon

Latest Information Update: 27 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmexa; Poseidon Pharmaceuticals
  • Class
  • Mechanism of Action Immunosuppressants; Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Transplant rejection; Urinary incontinence

Most Recent Events

  • 25 Nov 2003 This programme is still in active development
  • 22 Jun 2001 M&E Biotech is now called Pharmexa
  • 13 Sep 2000 NeuroSearch is collaborating with M&E Biotech on researching the immunosuppressive potential of the potassium channel modulators
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top